{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:04Z","timestamp":1792021624698,"version":"4.4.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtauto.2025.100311","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:14:23Z","timestamp":1756192463000},"page":"100311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Regulatory T cell therapy for Sj\u00f6gren's disease: From pathogenesis to targeted treatment"],"prefix":"10.1016","volume":"11","author":[{"given":"Zhi Feng Sherman","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta Y.","family":"Hoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien B.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Rischmueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-8396","authenticated-orcid":false,"given":"Yi Tian","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2025.100311_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.rdc.2008.08.003","article-title":"Genes and Sjogren's syndrome","volume":"34","author":"Cobb","year":"2008","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jtauto.2025.100311_bib2","article-title":"Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sj\u00f6gren\u2019s syndrome","volume":"23","author":"Wen","year":"2022","journal-title":"BMC Immunlogy"},{"key":"10.1016\/j.jtauto.2025.100311_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/acr.23707","article-title":"The incidence and prevalence of adult primary Sjogren's syndrome in New York county","volume":"71","author":"Izmirly","year":"2019","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jtauto.2025.100311_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jtauto.2025.100311_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: a systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/ar599","article-title":"Genetic aspects of Sjogren's syndrome","volume":"4","author":"Bolstad","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.jtauto.2025.100311_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coms.2013.09.002","article-title":"An update on epidemiology and current insights on pathophysiology","volume":"26","author":"Reksten","year":"2014","journal-title":"Oral Maxillofac. Surg. Clin."},{"key":"10.1016\/j.jtauto.2025.100311_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9093057","article-title":"Contributions of major cell populations to Sjogren's syndrome","volume":"9","author":"Witas","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib9","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.jtauto.2025.100311_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/JIR.S137024","article-title":"Review of autoantigens in Sj\u00f6gren\u2019s syndrome: an update","author":"Tong","year":"2017","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.jtauto.2025.100311_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sjogren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zeron","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jtauto.2025.100311_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2019.04.011","article-title":"Risk factors for caries development in primary Sjogren syndrome","volume":"128","author":"Berman","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.jtauto.2025.100311_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/1744666X.2016.1109449","article-title":"Early diagnosis of primary Sjogren's syndrome: EULAR-SS task force clinical recommendations","volume":"12","author":"Brito-Zeron","year":"2016","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtauto.2025.100311_bib15","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sjogren's syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.jtauto.2025.100311_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13060961","article-title":"The spectrum of extraglandular manifestations in primary Sjogren's syndrome","volume":"13","author":"Mihai","year":"2023","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116189","article-title":"Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients","volume":"10","author":"Papageorgiou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtauto.2025.100311_bib19","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.jtauto.2025.100311_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103084","article-title":"Primary Sjogren's syndrome is associated with increased risk of malignancies besides lymphoma: a systematic review and meta-analysis","volume":"21","author":"Zhong","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2025.100311_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020658","article-title":"The involvement of innate and adaptive immunity in the initiation and perpetuation of Sj\u00f6gren\u2019s syndrome","volume":"22","author":"Chivasso","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jtauto.2025.100311_bib22","article-title":"Distinct pathophysiologic pathways support stratification of Sjogren's disease based on symptoms, clinical, and routine biological data","author":"Nguyen","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib23","article-title":"Epithelial\u2013immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2025.100311_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2017.04.018","article-title":"Genetics of Sjogren's syndrome","volume":"182","author":"Teos","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib25","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1084\/jem.169.6.2191","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome","volume":"169","author":"Saito","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s40744-021-00334-8","article-title":"Sjogren's syndrome and viral infections","volume":"8","author":"Liu","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jtauto.2025.100311_bib27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/rheumatology\/key330","article-title":"Genetics and epigenetics in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Imgenberg-Kreuz","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jtauto.2025.100311_bib28","series-title":"Autoantibodies and Cytokines","author":"Ma\u015bli\u0144ska","year":"2018"},{"key":"10.1016\/j.jtauto.2025.100311_bib29","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.4049\/jimmunol.150.8.3615","article-title":"Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjogren's syndrome","volume":"150","author":"Kang","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib30","first-page":"398","article-title":"[Study on the relationship between primary Sjogren syndrome and HLA-DRbeta gene]","volume":"36","author":"Wang","year":"1997","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.jtauto.2025.100311_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/03009740500287517","article-title":"HLA class II allele polymorphism in Hungarian patients with primary Sjogren's syndrome","volume":"35","author":"Kovacs","year":"2006","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/sarh.2002.32557","article-title":"TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjogren's syndrome","volume":"31","author":"Anaya","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100311_bib33","first-page":"725","article-title":"DRB1\u221715 and DRB1\u221703 extended haplotype interaction in primary Sjogren's syndrome genetic susceptibility","volume":"16","author":"Jean","year":"1998","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2249.1998.00504.x","article-title":"HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS)","volume":"111","author":"Rischmueller","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib35","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.11103","article-title":"In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response","volume":"48","author":"Gottenberg","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100311_bib36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-3083.2001.00993.x","article-title":"Associations of MHC class II alleles in Norwegian primary Sjogren's syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen","volume":"54","author":"Nakken","year":"2001","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s12016-017-8606-7","article-title":"Myeloid populations in systemic autoimmune diseases","volume":"53","author":"Morell","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-3083.2006.01811.x","article-title":"Role of dendritic cells in Sjogren's syndrome","volume":"64","author":"Vogelsang","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1573397112666160714164149","article-title":"Update on pathogenesis of Sjogren's syndrome","volume":"13","author":"Sandhya","year":"2017","journal-title":"Curr. Rheumatol. Rev."},{"key":"10.1016\/j.jtauto.2025.100311_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib41","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1365-2362.2010.02342.x","article-title":"Autoimmune response and target autoantigens in Sjogren's syndrome","volume":"40","author":"Routsias","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.jtauto.2025.100311_bib42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jim.2016.07.003","article-title":"Muscarinic type 3 receptor autoantibodies are associated with anti-SSA\/Ro autoantibodies in Sjogren's syndrome","volume":"437","author":"Zuo","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jtauto.2025.100311_bib43","first-page":"4","article-title":"Alpha fodrin and the diagnosis of primary Sj\u00f6gren\u2019s syndrome; experience of a Rheumatology Centre in Bogota, Colombia","author":"Arteagaa","year":"2019","journal-title":"Rev. Colomb. Reumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib44","first-page":"1884","article-title":"Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome","volume":"29","author":"Tsunawaki","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072299","article-title":"Current state of knowledge on primary Sjogren's syndrome, an autoimmune exocrinopathy","volume":"9","author":"Parisis","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2017.03.007","article-title":"Insight into pathogenesis of Sjogren's syndrome: dissection on autoimmune infiltrates and epithelial cells","volume":"182","author":"Goules","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI63681","article-title":"IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis","volume":"123","author":"Huber","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtauto.2025.100311_bib48","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/imj.16395","article-title":"The diagnosis and misdiagnosis of Sjogren disease","volume":"54","author":"Lee","year":"2024","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.jtauto.2025.100311_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren's syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jtauto.2025.100311_bib50","first-page":"2387","article-title":"Candidate autoantibodies for primary Sjogren's syndrome: where are they now?","volume":"40","author":"He","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib51","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2020.01.029","article-title":"Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody","volume":"180","author":"Singh","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jtauto.2025.100311_bib52","first-page":"500","article-title":"Autoantibodies against alpha-fodrin in Sjogren's syndrome with neurological manifestations","volume":"31","author":"de Seze","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0022034510390811","article-title":"Salivary anti-Ro60 and anti-Ro52 antibody profiles to diagnose Sjogren's Syndrome","volume":"90","author":"Ching","year":"2011","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.jtauto.2025.100311_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00109-004-0529-0","article-title":"The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity","volume":"82","author":"Chen","year":"2004","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.jtauto.2025.100311_bib55","series-title":"Textbook of Pediatric Rheumatology","author":"Cassidy","year":"2005"},{"key":"10.1016\/j.jtauto.2025.100311_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/JIR.S137024","article-title":"Review of autoantigens in Sjogren's syndrome: an update","volume":"10","author":"Tong","year":"2017","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.jtauto.2025.100311_bib57","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1080\/15384101.2019.1656476","article-title":"alpha-Fodrin is required for the organization of functional microtubules during mitosis","volume":"18","author":"Nellikka","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jtauto.2025.100311_bib58","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/ard.2004.026419","article-title":"Anti-alpha-fodrin autoantibodies are not useful diagnostic markers of primary Sjogren's syndrome","volume":"64","author":"Sordet","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib59","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front. Immunol."},{"issue":"Suppl 126","key":"10.1016\/j.jtauto.2025.100311_bib60","first-page":"134","article-title":"Anti-Ro52 and\/or anti-Ro60 immune reactivity: autoantibody and disease associations","volume":"38","author":"Zampeli","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10409238.2019.1608902","article-title":"Ro60 and Y RNAs: structure, functions, and roles in autoimmunity","volume":"54","author":"Boccitto","year":"2019","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.jtauto.2025.100311_bib62","article-title":"Isolated anti-Ro52 identifies a severe subset of Sjogren's syndrome patients","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib63","first-page":"2310","article-title":"The value of separate detection of anti-Ro52, anti-Ro60 and anti-SSB\/La reactivities in relation to diagnosis and phenotypes in primary Sjogren's syndrome","volume":"40","author":"Deroo","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102724","article-title":"Anti-Ro60 and anti-Ro52\/TRIM21: two distinct autoantibodies in systemic autoimmune diseases","volume":"124","author":"Lee","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jtauto.2025.100311_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.autrev.2010.09.005","article-title":"Clinical and laboratory aspects of Ro\/SSA-52 autoantibodies","volume":"10","author":"Defendenti","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2025.100311_bib66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2019-215862","article-title":"Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands","volume":"79","author":"Takeshita","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib67","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4049\/immunohorizons.2300043","article-title":"Immunoassay detects salivary anti-SSA\/Ro-52 autoantibodies in seronegative patients with primary Sjogren's syndrome","volume":"7","author":"Kamounah","year":"2023","journal-title":"Immunohorizons"},{"key":"10.1016\/j.jtauto.2025.100311_bib68","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3389\/fimmu.2018.02362","article-title":"Gene expression profiling of lacrimal glands identifies the ectopic expression of MHC II on glandular cells as a presymptomatic feature in a mouse model of primary Sjogren's syndrome","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib69","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.4049\/jimmunol.168.11.5876","article-title":"HLA class II influences the immune response and antibody diversification to Ro60\/Sjogren's syndrome-A: heightened antibody responses and epitope spreading in mice expressing HLA-DR molecules","volume":"168","author":"Paisansinsup","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.787193","article-title":"Proteomics analysis of tears and saliva from Sjogren's syndrome patients","volume":"12","author":"Das","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jtauto.2025.100311_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12683","article-title":"Metabolomics analysis of saliva from patients with primary Sjogren's syndrome","volume":"182","author":"Kageyama","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib72","first-page":"1073","article-title":"Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins","volume":"21","author":"McCauliffe","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib73","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/art.42244","article-title":"In vivo generation of SSA\/Ro antigen-specific regulatory T cells improves experimental Sjogren's syndrome in mice","volume":"74","author":"Xu","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib74","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/acr.24597","article-title":"Antibodies to both Ro52 and Ro60 for identifying Sjogren's syndrome patients best suited for clinical trials of disease-modifying therapies","volume":"74","author":"Armagan","year":"2022","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jtauto.2025.100311_bib75","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2025.100311_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2014.02.004","article-title":"T cell epitope mimicry between Sjogren's syndrome Antigen A (SSA)\/Ro60 and oral, gut, skin and vaginal bacteria","volume":"152","author":"Szymula","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib77","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sjogren's syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtauto.2025.100311_bib78","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/BOR.0000000000000754","article-title":"Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis","volume":"32","author":"Narain","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"issue":"Suppl 4","key":"10.1016\/j.jtauto.2025.100311_bib79","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1186\/ar1007","article-title":"B cell depletion in autoimmune disease","volume":"5","author":"Gorman","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2025.100311_bib80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Suppl 4","key":"10.1016\/j.jtauto.2025.100311_bib81","doi-asserted-by":"crossref","first-page":"iv77","DOI":"10.1136\/ard.2005.042507","article-title":"How does B cell depletion therapy work, and how can it be improved?","volume":"64","author":"Clark","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib82","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sjogren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtauto.2025.100311_bib83","series-title":"Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj\u00f6gren's Syndrome","author":"Squibb","year":"2024"},{"key":"10.1016\/j.jtauto.2025.100311_bib84","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjogren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jtauto.2025.100311_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib86","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100311_bib87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib88","article-title":"Rituximab therapy for primary Sjogren's syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jtauto.2025.100311_bib89","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib90","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtauto.2025.100311_bib91","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtauto.2025.100311_bib92","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2025.100311_bib93","series-title":"ACR Convergence 2022","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019sSyndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","author":"Xu","year":"2022"},{"key":"10.1016\/j.jtauto.2025.100311_bib94","series-title":"A Study of TACI-Antibody Fusion Protein Injection (RC18) in Subjects with Primary Sj\u00f6gren's Syndrome","author":"RemeGen Co","year":"2021"},{"key":"10.1016\/j.jtauto.2025.100311_bib95","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"Dorner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib96","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1097\/MS9.0000000000002745","article-title":"Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review","volume":"86","author":"Fatima","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.jtauto.2025.100311_bib97","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sjogren's syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100311_bib98","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sjogren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jtauto.2025.100311_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary Sjogren's syndrome: the open-label extension phase of the ASAP-III trial","volume":"53","author":"de Wolff","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100311_bib100","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jtauto.2025.100311_bib101","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do regulatory T cells work?","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib102","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib104","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/imcb.12424","article-title":"Antigen-driven CD4(+) T-cell anergy: a pathway to peripheral T regulatory cells","volume":"99","author":"Eggenhuizen","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jtauto.2025.100311_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jtauto.2025.100311_bib106","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.4049\/jimmunol.176.8.4622","article-title":"MHC class II expression identifies functionally distinct human regulatory T cells","volume":"176","author":"Baecher-Allan","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib107","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/rheumatology\/kead070","article-title":"Regulatory T cells: a new therapeutic link for Sjogren syndrome?","volume":"62","author":"Ming","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jtauto.2025.100311_bib108","article-title":"Altered subgroups of regulatory T cells in patients with primary Sjogren's syndrome","volume":"9","author":"Lin","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jtauto.2025.100311_bib109","first-page":"2438","article-title":"T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjogren's syndrome","volume":"34","author":"Li","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100311_bib110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/08916930802282651","article-title":"Quantification and molecular characterization of regulatory T cells in connective tissue diseases","volume":"42","author":"Banica","year":"2009","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jtauto.2025.100311_bib111","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2353\/ajpath.2008.080246","article-title":"Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors","volume":"173","author":"Christodoulou","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jtauto.2025.100311_bib112","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12865-022-00524-1","article-title":"Low-dose interleukin-2 can improve salivary secretion but not lymphocyte infiltration of salivary glands in a murine model of Sjogren's syndrome","volume":"23","author":"Wen","year":"2022","journal-title":"BMC Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-4-50","article-title":"The four types of Tregs in malignant lymphomas","volume":"4","author":"Wang","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jtauto.2025.100311_bib114","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semcancer.2012.03.004","article-title":"What are regulatory T cells (Treg) regulating in cancer and why?","volume":"22","author":"Whiteside","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jtauto.2025.100311_bib115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coi.2020.07.004","article-title":"New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression","volume":"67","author":"Mikami","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib117","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2217\/imt.15.79","article-title":"Manipulating regulatory T cells: a promising strategy to treat autoimmunity","volume":"7","author":"Zhang","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtauto.2025.100311_bib118","doi-asserted-by":"crossref","first-page":"eadn2404","DOI":"10.1126\/scitranslmed.adn2404","article-title":"A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes","volume":"16","author":"Bender","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40259-020-00462-7","article-title":"Administration of CD4(+)CD25(high)CD127(-)FoxP3(+) regulatory T cells for relapsing-remitting multiple sclerosis: a phase 1 study","volume":"35","author":"Chwojnicki","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.jtauto.2025.100311_bib120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2025.100311_bib121","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2025.100311_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jtauto.2025.100311_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jtauto.2025.100311_bib124","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jtauto.2025.100311_bib125","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2025.100311_bib126","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jtauto.2025.100311_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: a new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jtauto.2025.100311_bib129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clim.2016.09.001","article-title":"IgV peptide mapping of native Ro60 autoantibody proteomes in primary Sjogren's syndrome reveals molecular markers of Ro\/La diversification","volume":"173","author":"Wang","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2013.03.015","article-title":"Long-term Ro60 humoral autoimmunity in primary Sjogren's syndrome is maintained by rapid clonal turnover","volume":"148","author":"Lindop","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sjogren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100311_bib132","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jtauto.2025.100311_bib133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jcyt.2020.07.001","article-title":"Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies","volume":"22","author":"Iwaszkiewicz-Grzes","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtauto.2025.100311_bib134","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/imm.12983","article-title":"Regulatory T cells control epitope spreading in autoimmune arthritis independent of cytotoxic T-lymphocyte antigen-4","volume":"155","author":"Yang","year":"2018","journal-title":"Immunology"}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:22:08Z","timestamp":1765358528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909025000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":134,"alternative-id":["S2589909025000462"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100311","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory T cell therapy for Sj\u00f6gren's disease: From pathogenesis to targeted treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100311"}}